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Abstract
The zebrafish is a vertebrate model compatible with the paradigms of drug discovery. The small size and transparency of
zebrafish embryos make them amenable for the automation necessary in high-throughput screenings. We have developed
an automated high-throughput platform for in vivo chemical screenings on zebrafish embryos that includes automated
methods for embryo dispensation, compound delivery, incubation, imaging and analysis of the results. At present, two
different assays to detect cardiotoxic compounds and angiogenesis inhibitors can be automatically run in the platform,
showing the versatility of the system. A validation of these two assays with known positive and negative compounds, as
well as a screening for the detection of unknown anti-angiogenic compounds, have been successfully carried out in the
system developed. We present a totally automated platform that allows for high-throughput screenings in a vertebrate
organism.
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Introduction
The development of small-molecule therapeutics by target-
directed strategies has been accelerated thanks to advances in
genomic research, combinatorial chemistry and laboratory auto-
mation with development of high and ultrahigh-throughput
screening (HTS) technologies [1]. However, although the target
based approach is clearly advantageous from a scientific and
practical point of view, it does not translate into a high success rate
for novel targets (only 3% of drugs designed against a novel target
reach preclinical development) [2]. Because of these problems, the
pharmaceutical industry is increasingly focusing on known targets
and looking for new indications for existing drugs, but this can
only be a temporary solution because the number of such
possibilities is limited. The important question is whether other
approaches might be more suitable for the identification of novel
treatments. It has been proposed that better models for drug
testing are needed to improve the discovery of new drug
candidates and whole organisms could provide such models [3],
[4]; [5].
An important advantage of organism-based chemical screening
is the fact that compounds are tested in the context of an intact
organism rather than under artificial in vitro conditions. The cells of
a whole organism are in their normal context and are non-
transformed. The embryo contains many distinct cell types,
making it theoretically possible to identify compounds that have
tissue-specific effects or demonstrate deleterious side effects on
complex developmental or physiological processes. The presence
of a whole organism’s metabolism permits the identification of
compounds that become active as metabolites and the lead
identification can be done without a detailed knowledge of the
targets or molecular pathways implicated in a specific disease [6],
[7]. Small molecules discovered by virtue of their ability to induce
a specific desirable phenotype in a whole organism are likely to
fulfill requirements needed by promising drug candidates to enter
in clinical development. They have to be cell-permeable, devoid of
obvious toxicities, effective and possess favorable pharmacody-
namic and pharmacokinetic profiles. Drug discovery in the whole
organism, therefore, combines screening and animal testing in one
step [8]. Animal models to be employed for organism-based
chemical screens have to be small, low cost and compatible with
simple culture conditions.
The nematode Caenorhabditis elegans and the fruit fly Drosophila
melanogaster are popular genetic model organisms that have been
used as screening tools in drug discovery [9]. An important
limitation of invertebrate models is, however, the fact that they
lack many complex organs, such as a cardiovascular system, an
immune system and kidneys, that are relevant to human biology
and physiology [8]. Among the vertebrate models, zebrafish
embryos are particularly well suited for whole organism chemical
screening because they are small, can be obtained in high
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and are optically transparent [10]. Embryos fit readily into
microwell plates and compounds can be directly applied into the
embryo medium [11]. Some manual screenings have been
reported using zebrafish embryos [12], [13], [6], [14], [15],
[16]. Recently, investigators have begun to adapt zebrafish to
HTS protocols [17], [18], [19], [20], [21]. In all these examples
automated software able to analyze images (for compounds that
alter angiogenesis [18], [19] or mutants with retinal axon guidance
alterations [20] or software able to analyze heart rate [17] and
locomotor activity [21]) have been developed. Nonetheless,
automation and integration of the whole screening process, from
the embryo dispensation, compound treatment, incubation,
phenotypic readout and analyses of the results have never been
reported for zebrafish.
The goal of this work was to develop a fully automated platform
for in vivo high-content and high-throughput screenings using
zebrafish embryos as a whole-organism model. We have focused
on the development of two different bioassays based on their
interest for pharmaceutical companies, the availability of zebrafish
tools and the previous knowledge of the transgenic lines chosen.
First, a cardiotoxicity assay to detect compounds that inhibit
the ether-a-go-go-related-gene (ERG) potassium channel was set
up. ERG blockade leads to an impairment of potassium outflow
from the cell and consequently a disruption of the action
potential, which is related to a prolongation of the QT interval
in the electrocardiogram. The QT prolongation detection has
extensively been used as a cardiotoxicity marker [22]. Current
systems for detection of human ERG (hERG) inhibition are in
vitro models which have disadvantages such as lack of evidence
for the crosstalk of mechanisms. Zebrafish have been proposed
as an experimental model to determine zebrafish ERG (zERG)
inhibition [23] as the main mechanism of action. zERG has
been identified and an 80% homology to the human protein
has been postulated [24]. Here we will use a transgenic line
expressing a GFP protein under the control of a myocyte
specific promoter (Cmlc2) to analyze the effect on the heart
function of a battery of compounds.
Second, an efficacy assay for detection of compounds that
inhibits angiogenesis has been developed. Angiogenesis, the
process of new blood vessel formation from pre-existing ones,
plays a key role in various physiological and pathological
conditions [25]. Many of the genes involved in the angiogenesis
process in higher vertebrates (vascular endothelial cell growth
factors (VEGF), fibroblast growth factors (FGF), ephrin receptors,
angiopoietins, etc) are conserved and have the same function in
zebrafish [26], [27], [28], [29]. Blood flow begins in the zebrafish
embryo at , 24 hours post-fertilization (hpf). Shortly after this, the
angiogenic vessels that perfuse the trunk of the embryo (interseg-
mental vessels, ISVs) sprout from the vasculogenic vessels (dorsal
aorta (DA) and posterior cardinal vein (PCV)). The existence of
transgenic zebrafish that express green fluorescent protein GFP
under the control of specific promoters of the vascular system (i.e.
Flk1 and Fli1), allows direct observation of ISVs development and
defects in this process.
In this report, we present how the automated platform has been
established. To show the flexibility of the platform designed, the
two different bioassays described for detection of cardiotoxicity or
angiogenesis inhibition have been successfully set up and
validated. Our results support zebrafish embryos as an in vivo
bioassay tool that can contribute to several aspects of the drug
development process, including drug target identification, lead
compound discovery and detection of drug toxicity.
Results
Our HTS platform was designed to avoid manual manipu-
lation of zebrafish embryos and achieve fully automated
screening assays aiming for the highest possible throughput
and minimizing human errors. The platform could be divided
into a physical robotic system and an extensive software layer
spread in different levels (1) the operation of the stand-alone
devices, (2) the control of the platform, (3) the analysis of the
images and the results and (4) the Laboratory Information
Management System (LIMS).
Instrument Configuration
The robotic system is comprised of several devices (plate hotel,
embryo sorter, liquid handling, automatic incubator and micro-
scope) that were individually tested and optimized before final
integration into the complete process. A robotic arm allows the
automatic transport of the assay plates between instruments
(Figure 1).
The transgenic lines employed to automate the experiments
expressed the fluorescent protein copGFP. To be able to
dispense one embryo per well we optimized the different
parameters affecting the sorter performance, which are: delay,
sorting criteria and width. Optimizing the delay minimizes
undesired results such as empty wells, doublets or triplets. The
sorting criteria parameters chosen were the height of the GFP
peak (indicates GFP intensity expression) and the particle size
(indicates the length of the embryo) measured in the signal
detected using the Profiler module (Figure 2 A, B). Proper
thresholds were established to assure that only embryos in the
correct stage showing enough fluorescence were dispensed.
These values resulted in one third of the embryos located in the
sorter reservoir (approximately 270 embryos) to be finally
dispensed in the assay plate within 3 to 5 minutes with a rate of
doublets/empties lower than 5% on average. After sorting, we
evaluated heartbeat, morphology, embryo development and
pigmentation and no differences were found compared to
manual dispensation (data not shown).
Variation in volume of the dispensed drop had to be considered
to establish the total volume in the well. The drop size, defined by
the width parameter was monitored during the parameterization
process. We determined that the variation of the drop size should
not exceed 10% of the total final volume in the well. Since this
variation was slightly higher in 48 hpf Cmlc2:copGFP embryos
(73612 ml for a final volume of 100 ml) a leveling step (described
next) was introduced. In the case of 24 hpf Flk1:copGFP embryos,
Figure 1. HTS platform layout. The figure shows all the components
of the platform: master PC, embryo sorter, two liquid handlings (LH1
and LH2), plate hotel, incubator and reader. The robotic arm in the
central part transports the plate to all the devices.
doi:10.1371/journal.pone.0036690.g001
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180 ml) satisfied the established criteria and no leveling step was
necessary.
Two liquid handling devices were integrated in the platform to
allow the performance of parallel operations, thus improving the
throughput of the process. These two devices were used for the
addition of compounds, the leveling step in the cardiotoxicity assay
(aspiration of the exceeding volume dispensed with the embryo)
and the tricaine addition in the angiogenesis assay.
A critical step during the platform integration was the image
acquisition. The microscope and the camera were configured to
scan the assay plate well by well. A macro for the scanning process
and image acquisition of each assay type was developed using
AxioVision software. For the cardiotoxicity assay, a video of the
fluorescent heart was required for the posterior automated image
analysis. First, the heart of the embryos had to be identified. For
this purpose the 1.256 objective and the fluorescent light were
used and the heart was identified by its intensity and area.
Afterwards, the 106 objective was used to (1) check if the heart
was still in the field of view (by measuring intensity and area) and
(2) the autofocus was applied to get an in focus heart. The image
containing the heart was cropped to avoid unnecessary informa-
tion and a sequence of 512 frames at 30 frames per second was
recorded.
The angiogenesis assay required a fluorescent image, then a
scan per well was performed to identify the embryo. Once
identified, the embryo was segmented according to determined
thresholds of intensity and area, centered in the field of view and
autofocused. The tail region of the embryo was focused avoiding
the head area and a fluorescent image was acquired for processing
by the image analysis software.
Finally, in both assays, cardiotoxicity and angiogenesis, a bright-
field image of each well was taken to evaluate the embryos’ general
condition.
Software Development
In this section the overall control of the platform, the specific
image analysis software developed for each assay and the data
management are described.
The integration of all the devices required a control system
programmed to automatically run the different assay types. It
operates using a configuration file that specifies the features of an
assay plate. In order to plan the process for a set of plates for an
assay, a scheduler module was implemented. Each location
corresponds to a task of the assay and is shown as a differently
colored bar in the screen (Figure S1).
The image analysis program for the Cardiotoxicity assay was
based on the processing of the videos to obtain a periodic signal of
the cardiac motion automatically and independent to the embryo
position. A custom-made analysis software (Cardio v3.0.0.5) was
generated (in collaboration with the technological center Vicom-
tech) to detect the heart rate, the presence of alterations in the
frequency of atrial and ventricular contraction (arrhythmia) and
the absence of heartbeat (cardiac arrest).
The detection of the heart beat frequency was based on the
frequency spectrum analysis of the Euclidean Distance (ED) signal
(built as the ED between the frames of the video referred to a
reference frame calculated with the mean values of intensity for
homogeneous zones). Obtaining the periodogram using the
Discrete Fourier Transform (DFT), and modifying it to avoid
undesired effects, the heart beat frequency was given by its first
significant frequency (Figure 3 A).
For embryos with arrhythmia (A), the sinusoidal course of the
ED signal was disrupted due to the irregular beating of the heart,
i.e. the different beating frequency of each chamber. The
classification of the arrhythmia cases was therefore based on the
number of significant frequencies detected in the DFT of the ED
signal (Figure 3 B).
For cardiac arrest (D) detection, a threshold was defined for the
amplitude between maxima and minima of the Optical Flow
Figure 2. Sorter embryo profiles. The figure shows a representative example of one embryo profile from Cmlc2:GFP at hpf 48 hpf (A) or Flk1:GFP
at 24 hpf (B), provided by COPAS sorter. Two parameters are represented in the Y axis, optical density (blue line) and intensity of the fluorescence
(green line) that are scaled differently (maximum of 1.024 and 65.536 respectively). The particle size is measured as the time of detection and is
represented in X axis. Sorted embryos should be in a defined interval of length and the fluorescence peak above the established threshold (green
horizontal line) to be dispensed; (5000–7500 ms and 170 a.u for Cmlc2:GFP embryos and 3050–7000 ms and 130 a.u for Flk1:GFP embryos). a.u:
arbitrary units.
doi:10.1371/journal.pone.0036690.g002
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brightness for each frame referred to a reference frame). The low
level of movement that appeared in dead embryos produced low
values of amplitude indicating cardiac arrest (Figure 3 C).
Reliability of the image analysis software was tested by
comparing the software output to manual analysis of the videos.
The data showed that the automatic calculation of the number of
heartbeats coincided with manual counting in 98.4% of the cases.
To measure the quality of detection of no effect, a total of 120
videos were analyzed and 93.3% of them were correctly classified.
For arrhythmia and cardiac arrest effects, a total of 1324 and 1544
videos were evaluated and the percentages of those correctly
classified were 95.6% and 97.5% respectively.
In the angiogenesis assay, the fluorescent images taken were
processed using AxioVision 4.6.3 and a macro was developed to
quantify an indirect measure of the area of the ISVs. Automatic
image analysis is a fast method to identify positive compounds and
can detect small variations in the width of the vessels indicating an
effect that could not be detected by human eye. However, we
usually include a manual counting to offer a more detailed
measurement of effect.
In the automatic analysis of angiogenesis, it is first necessary to
perform a sequence of automated filtering functions on the image
to extract information, define the region of interest (ROI), that in
this case is the part of the tail containing the ISVs, and allow the
measurement of the embryo length. Recovering a previous image,
new filtering functions are applied to the ROI. A gradient image
containing the ISVs, the DLAV (Dorsal Longitudinal Anastomotic
Vessel), the PCV and the DA is created. Next, fluorescent areas
that should not be quantified are discarded. Finally, only the areas
comprised between the ISVs, the DLAV and the PCV or the DA
are measured (Figure 4). In that way, when the vessels are
incomplete or the DLAV is not present, an enclosed area is not
present and therefore not measured. We have found that the
inhibition of angiogenesis can be more efficiently detected in this
way than when the direct measurement of the fluorescent area of
the ISVs is applied.
The means obtained from the treated embryos were compared
with the control mean. When statistically significant differences
were detected a deeper analysis was done manually. In this case
the parameters quantified were:
1. The total number of ISVs present in the trunk of the embryos
(from where the largest bulge of the yolk ends to the end of the
tail).
2. Number of complete ISVs (reached the dorsal part of the
embryo and formed the DLAV).
The performance of the software developed for image analysis
was checked over a training set of 450 tests (every test is a group of
10 embryos) manually evaluated that included control and treated
embryos. Two different compounds (KRN633 and AG1478) at
different concentrations were used to cover different degrees of
effects. In 92% of the cases manual and automatic results
coincided and, most importantly, only 1.8% of the tests in which
an effect was induced, were not detected. In this case, a very slight
anti-angiogenic action was always present.
Figure 3. Image analysis of the heart rate. The figure shows the analysis of the heart rate of a representative control (A), arrhythmic heart (B) and
cardiac arrest (C). OF and ED algorithms are applied for the analysis of each video. Only when the OF is above a specific threshold FFT is applied to ED.
Control and arrhythmic hearts are classified based on the number of the significant frequencies detected in the FFT, one for control (A) two or more
for arrhythmic (B). (C) OF representative of a dead embryo. In FFTs, Periodogram is shown in blue, Original Fourier Transform of the ED signal in black
and Heartbeat is shown in red.
doi:10.1371/journal.pone.0036690.g003
Zebrafish Drug Screening Platform Validation
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36690In order to run the image analysis process off-line after the
image acquisition and to generate the results file, a data processing
program was developed. This program gets the data from the
database and performs the statistical analysis (SPSS software).
Finally, a result file (in Excel and Word formats) was released
containing descriptive statistics and graphs.
Finally, a tailor made LIMS was developed (in collaboration
with the Technological Center Tekniker) to support the activity of
the laboratory and manage the information in the screening
process. The LIMS receives data about compounds, embryos or
plates (either manually or from other databases), tracks the
information of the screening and shows all the relevant data of an
assay and its final results files.
Validation of the Cardiotoxicity Assay
The cardiotoxicity screening was performed at a specific and
controlled temperature (27.5uC60.5) since small changes in this
parameter led to significant differences in heart rate (Figure S2, A).
We also established that the interval for the stage of the embryos at
the beginning of the analysis should be between 51 and 57 hpf
since no differences in heart rate were found in embryos between
these two stages (Figure S2, B).
Next, we selected three different effects that the system should
identify (bradycardia, arrhythmia and cardiac arrest) in order to
establish a useful assay for cardiotoxicity detection. To define a
cutoff for bradycardia, the antipsychotic drug Thioridazine, which
caused bradycardia in zebrafish embryos at 5 mM, was chosen. A
group of approximately 100 embryos was treated with this
compound. The receiver operating characteristic (ROC) curve
exclusion model showed that 36.5 beat per 15 second was the
threshold for bradycardia identification with sensitivity of 78% and
a specificity of 70% (Figure S3). It is important to note that this
cutoff point coincides when using other compounds such as
Estradiol and Testosterone to induce bradycardia [30], [31] (data
not shown).
Abnormal QT interval prolongation is a relevant cardiotoxicity
marker because of its association with ventricular electric
instability, which could induce polymorphic ventricular arrhyth-
mias known as ‘‘torsade de pointes’’ [22]. Most QT-prolongation
inducers exert their effect by inhibiting hERG, a delayed rectifier
potassium channel. In zebrafish, inhibition of zERG using
morpholinos leads to a specific phenotype called 2:1 arrhythmia
[24] that is the equivalent to an AV (Atrio-Ventricular) block in
mammals. There is no evidence of a similar phenotype in other
experimental models or when inhibiting other cardiac ion
channels. This supports the linkage between type 2:1 arrhythmia
and zERG inhibition in zebrafish.
In order to detect zERG inhibition automatically, we analyzed
4 QT prolongation inducers (Terfenadine, Cisapride, Astemizole
and Haloperidol) in a range of concentrations (0.1, 1, 5, 10, 20 and
50 mM) and compared them with 2 non-QT inducers (Digitoxine
and Nitrendipine). Results showed that Terfenadine, Cisapride
and Haloperidol were detected as potential QT-prolongation
inducers at 5 mM and Haloperidol at 1 mM (Table 1). It is
important to note that the mentioned concentrations do not reflect
the real dose in the embryos. Bioavailability studies should be
performed to evaluate it. In addition, a specific repertoire of
phenotypes from no effect (Movie S1) and bradycardia (Movie S2)
to heart failure (Movie S5) through severe atrio-ventricular 2:1
arrhythmia (Movie S3) and ventricular failure (Movie S4) were
observed, as previously reported [24]. This progression was not
seen with other cardiotoxic drugs such as Digitoxine and
Nitrendipine which do not cause a prolongation of the QT
interval. This finding reveals that our method can specifically
predict drug-induced QT prolongation mediated by a blockade of
the HERG channel.
To characterize the specificity and sensitivity of the method, 35
compounds were chosen according to their known therapeutic
effects in humans and to the drug targets, including different ion
channel proteins and regulatory pathways. The drugs were diluted
in DMSO and blind screened in a concentration range between 1
and 200 mM. Based on their predominant effects they were
automatically classified in 4 categories: No effect, cardiac arrest,
bradycardia, and arrhythmia. The 35 compounds included: 17
QT prolongation related arrhythmia inducers (15 HERG channel
blockers and 2 IKs channel blockers), 11 bradycardia inducers,
2 non-QT related arrhythmia inducers, 1 cardiac arrest inducer
and 4 without effect. Fourteen out of 17 QT prolongation inducers
were correctly detected, with them all being HERG channel
inhibitors. All the other compounds were properly classified
Figure 4. Images analysis for ISVs formation. The figure shows the different steps in the process of image analysis for the determination of the
anti-angiogenesis effect. Control embryo (A, B, C and D); embryo treated with KRN633 (A’, B’, C’ and D’). (A) and (A’) are the original images acquired
by the microscope; (B) and (B’) are images showing the segmentation between the head and the tail of the embryo to separate the ROI and measure
the length; (C) and (C’) are images corresponding to an intermediate step in the filtering process where all the vessels in the tail can be identified; (D)
and (D’) are images presenting the area enclosed between ISVs and DLAVs (in white) that are the ones to be quantified.
doi:10.1371/journal.pone.0036690.g004
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detecting of QT prolongation inducers mediated by an HERG
blockade (observed as type 2:1 arrhythmias) but also compounds
that affect calcium channels (detected as bradycardia inducers) and
sodium channels (detected as bradycardia in the case of the sodium
channel blocker Lidocaine or as 2:1 arrhythmia in the case of the
sodium channel activator SDZ-201106). Moreover, the data
suggest that it is possible to distinguish between QT related and
non-QT related arrhythmias. The method showed a specificity of
90.3% and sensitivity of 100% for the compounds tested (Table 2).
Next, we assessed the repeatability of the method. For this, three
compounds (Lidocaine, Thioridazine and Haloperidol) with
known effects on heart rate at 5 and 50 mM were tested. A total
of 10 plates each containing 20 embryos per condition and 20
controls were analyzed. An interassay coefficient of variation (CV
= standard deviation x100/mean) was calculated for each
compound. The average coefficient of variation (CV) value was
5.2% (Table 3), indicating that the assay developed is highly
repeatable.
Validation of the Angiogenesis Assay
To validate the angiogenesis assay developed in the HTS
platform, 18 positive compounds were selected based on their
capacity to inhibit known regulators of angiogenesis, including
different tyrosine kinase inhibitors as VEGF receptors (VEGFRs),
FGF receptors (FGFRs), PDGFR (platelet-derived growth factor
receptor), etc. On the other hand, 10 compounds contained in
the LOPAC
1280 library previously tested in cellular HUVECs
[32] and xenopus [33] screenings, which did not have an
inhibitory action against angiogenesis, were used as negative
items. The name and target of the compounds tested is shown in
Table S1.
All these compounds were tested following the procedure
described in the Methods section. A curve of six concentrations
(0.01, 0.1, 1, 10, 30 and 100 mM) was performed for all of them.
Only for the items that specifically inhibited angiogenesis, a second
curve with specific concentrations was developed to calculate the
IC50 for the two parameters manually quantified for the detection
of the anti-angiogenic effect (total number and complete number
of vessels). IC50 was calculated when a clear dose-dependent anti-
angiogenesis effect was detected. Otherwise, the minimum dose at
which the inhibition of angiogenesis was observed is shown
(Table 4). 15 of the 18 positive compounds were detected as
angiogenesis inhibitors in our assay (with only Tie-2 kinase
inhibitor, Fumagillin and Hif-1 inhibitor not detected). None of
the negative compounds tested showed any anti-angiogenesis
effect. Therefore, the values of specificity and sensitivity are 83%
and 100% respectively, what indicates that the assay developed
allows for the detection of anti-angiogenic compounds with high
specificity and sensibility in an in vivo model.
To determine the assay robustness, 3 different experiments were
carried out with some of the positive compounds representative of
different targets. They were tested at one dose close to the IC50 or
the effective concentration and the CV was calculated for the total
fluorescence area of the ISVs and the total number of vessels
quantified automatically and manually respectively. The results
obtained (Table 5) indicate that the assay developed is highly
repeatable with CV values always lower than 20%, except for
KRN633 and Sorafenib, which were slightly higher when the
fluorescence intensity was the parameter measured.
Two clearly different phenotypes were detected for the positive
anti-angiogenic compounds described before. In KRN633,
ZD6474, Sunitinib, Sorafenib, PD166866, PDGFR tyrosine
kinase inhibitor, AG1478, Indirrubin, 2-Methoxyestradiol and
Paclitaxel treated embryos the formation of ISVs was perturbed
with defective or total absence of sprouting. This effect was dose
dependent and higher concentrations caused more intense
phenotypes, with low numbers or absence of vessels and vessels
stalled at the boundary between the notochord and the neural tube
(Figure 5, A). However, compounds such as PD173074, AG-1296,
NS-398, Bosutinib and NVP-BEZ235 showed a moderate effect
that did not increase with higher doses, with little or no decrease in
the total number of ISVs present but with the presence of thinner
vessels (some of them incomplete) that do not always form the
DLAV (Figure 5, A). While the first group of compounds is
probably inhibiting initial essential steps in angiogenesis (sprouting
and extension), the second group is probably more related to
targets that participate in the proper maturation of the ISVs and/
or DLAV formation.
The anti-angiogenic activity of the second group of compounds
described was further demonstrated by studying their effects in
embryos at 72 hpf, when circulation is already present. PD173074,
AG-1296, Bosutinib and NVP-BEZ235 treated embryos showed
impaired blood circulation and presented thinner ISVs that were
disrupted in some cases (Figure 5 B). The absence of blood
circulation indicates that even if vessels were initially developed
they were not functional. NS-398 could not be tested at 72 hpf
since it was lethal at 48 hpf doses, which inhibited angiogenesis.
Therefore, different phenotypes associated with inhibition of
different steps of angiogenesis regulation (sprouting and matura-
tion) can be detected with this method.
Finally, a screening of 240 compounds representative of the
BioFocus SoftFocusH library was carried out and the enzyme
Phosphorilase Kinase was identified as a new potential targets for
antitumoral therapeutics [34]. Therefore, the assay developed
constitutes a powerful tool for library screening that will detect not
only inhibitors for many of the known pathways that regulate
angiogenesis, but also inhibitors of unknown regulators that could
constitute new targets in drug development.
Discussion
The results shown in this article support the use of zebrafish
embryos in an HTS system. Zebrafish provide several advantages
over other in vivo models. Their small size, transparency at early
development stages, ability to grow in liquid medium and high
number of offspring make them amenable to high-throughput
Table 1. Dose-effect analysis of QT and non-QT prolongation
inducers.
COMPOUND CONCENTRATION
0.1 mM1 mM5 mM1 0 mM2 0 mM5 0 mM
Terfenadine N B A A HF HF
Cisapride N N A VF HF HF
Astemizole N A HF HF HF HF
Haloperidiol N N A VF VF HF
Digitoxin ND ND N B HF HF
Nitrendipine ND N B B VF HF
Four QT prolongation inducers (Terfenadine, Cisapride, Astemizole and
Haloperidiol) and 2 non-QT prolongation inducers (Digitoxin and Nitrendipine)
were tested on 48 hpf zebrafish embryos. Predominant observed effects are
indicated: normal heart rate (N), bradycardia (B), 2:1 arrhythmia (A), ventricle
failure (VF), heart failure (HF).
doi:10.1371/journal.pone.0036690.t001
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candidates for drug discovery strategies at the outset of the
screening process as they are able to identify unwanted
compounds at the earliest stages of drug development [35].
However, the lack of a totally automated system to distribute the
embryos, add the treatments, acquire the images and analyze and
store the data has prevented investigators from using zebrafish
routinely in screening strategies due to the time-consuming
features of these types of projects. Although other authors have
focused on the image analysis for automation of zebrafish assays
[36], [17], [18], [19], [20], [21], to our knowledge no data
reporting a completely automated process has been published.
Our goal in this work was to integrate all the operations required
to complete an assay, providing the advantages of automated
processes such as consistency between runs, automatic tracking of
data, throughput and standardization, thus preventing variability
due to human errors.
The design of the platform enables the use of the devices in
several combinations and the addition of new instruments is
possible. The equipment can be run integrated but also in stand-
alone mode which is especially interesting in the case of the
reader, image analysis and generation of the results for assays
that require a repeatable readout but a complicated processing of
the sample.
The developed system allows a throughput of 8 (cardiotoxicity)
to 18 (angiogenesis) compounds per hour (with a sample size of 10
Table 2. Screening of 34 small bioactive compounds.
REFERENCE COMPOUNDS FAMILY
CARDIAC EFFECT IN
HUMANS
CARDIOTOXIC EFFECT IN
ZEBRAFISH CLASSIFICATION
Lidocaine Antiarrhythmic Bradycardia Bradycardia TP
Flecainide Antiarrhythmic QT-prolong. Arrhythmia 2:1 TP
Propafenone Antiarrhythmic QT-prolong. Arrhythmia 2:1 TP
Amiodarone Antiarrhythmic QT-prolong. Arrhythmia 2:1 TP
Propranolol Beta-Blocker Bradycardia Bradycardia TP
Timolol Beta-Blocker Bradycardia Bradycardia TP
Thioridazine Antipsychotic QT-prolong. Arrhythmia 2:1 TP
Haloperidol Antipsychotic QT-prolong. Arrhythmia 2:1 TP
Ziprasidone Antipsychotic QT-prolong. Bradycardia FN
Pimozide Antipsychotic QT-prolong. Arrhythmia 2:1 TP
Sertindol Antipsychotic QT-prolong. Arrhythmia 2:1 TP
Risperidone Antipsychotic QT-prolong. Arrhythmia 2:1 TP
Fluoxetine Antidepressant Arrhythmia Arrhythmia TP
Doxorrubicin Antitumoral No effect No effect TN
Tamoxifen Antitumoral Arrhythmia Arrhythmia TP
Lapatinib Antitumoral No effect No effect TN
Verapamil Calcium blocker Bradycardia Bradycardia TP
Diltiazem Calcium blocker Bradycardia Bradycardia TP
Nitrendipine Calcium blocker Cardiac arrest Cardiac arrest TP
Terodiline Calcium blocker QT-prolong. Arrhythmia 2:1 TP
Pilocarpine Colinergic agonist No effect No effect TN
Nicotine Colinergic agonist Bradycardia Bradycardia TP
Astemizol Antihistamine QT-prolong. Arrhythmia 2:1 TP
Terfenadine Antihistamine QT-prolong. Arrhythmia 2:1 TP
Fexofenadine Antihistamine No effect No effect TN
Halofantrine Antiinfective QT-prolong. Arrhythmia 2:1 TP
Foscarnet Antiinfective Bradycardia Bradycardia TP
Cisapride Gastrointestinal agent QT-prolong. Arrhythmia 2:1 TP
Estradiol Hormones Bradycardia Bradycardia TP
Testosterone Hormones Bradycardia Bradycardia TP
L-768763 Iks blocker QT-prolong. Bradycardia FN
Chromanol 293b Iks blocker QT-prolong. No effect FN
SDZ-201106 Ina opener QT-prolong. Arrhythmia 2:1 TP
Digitoxin Other Bradycardia Cardiac arrest TP
Ketanserin Other Bradycardia Bradycardia TP
The table shows the compounds used for validation, their family and their cardiotoxic effects assessed in humans and zebrafish.TN (true negative), TP (true positive), FN
(false negative), FP (false positive).
doi:10.1371/journal.pone.0036690.t002
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design of the platform would duplicate the throughput of the
assays by using a second microscope as the scanning of the plate is
the bottleneck of the platform. Although automated systems in vitro
provide higher throughputs, the amount of compounds analyzed is
far higher than other in vivo assays in vertebrate models. High-
throughput screens in cells to evaluate HERG inhibition have
been developed [37], [38], [39]. These systems use hERG stably
transfected cell lines and patch-clamp technique to evaluate
current amplitude. In the method described by Guthrie et al., 37
compounds can be analyzed per hour. Each compound was used
in 8 wells, generally allowing between 3 and 8 successful cells (data
points) at the 1 concentration. Even if the throughputs of in vitro
assays tend to be higher (the throughput of the patch clamp
automated technique is 4 fold higher than our cardiotoxicity
method) we have the advantages provided by an in vivo model such
as testing compounds in an intact organism that allows to
detection of tissue-specific effects that requires the interaction of
different cell types as well as side effects during development. An
example of the advantage of using zebrafish for cardiotoxicity
detection was found in the classification of Verapamil. While in
vitro assays target this compound as a potent HERG blocker [40],
[41], studies in mammals show that it does not induce a
prolongation of the QT-segment [42], [43]. This result agrees
Table 3. Repeatability assessment.
PREDOMINANT
EFFECT
REFERENCE
COMPOUNDS INTER-ASSAY CV
No effect Lidocaine 5 mM 3.2%
Bradycardia Lidocaine 50 mM 2.5%
Bradycardia Thioridazine 5 mM 3.7%
Arrhythmia Thioridazine 50 mM 7.3%
Arrhythmia Haloperidol 5 mM 5.4%
Cardiac arrest Haloperidol 50 mM 9.3%
Calculation of the Coefficient of Variation (C.V) for ten independent
experiments for the compounds and concentration indicated.
doi:10.1371/journal.pone.0036690.t003
Table 4. Summary of the results obtained after angiogenesis assay validation.
COMPOUND ANGIOG. INHIBITION IC50 (mM) EFECTIVE CONCENTRATION (mM)
T.V. C.V.
KRN633 Yes 0.035 0.026 –
ZD6474 (Vandetanib) Yes – – 100
Sunitinib malate Yes 2.6 1.7 –
Sorafenib Tosylate Yes 0.78 0.53 –
PD173074 Yes – – 100
PD166866 Yes 43.9 16 –
AG-1296 Yes – – 20
PDGFR tyr kin inhibitor V Yes 0.19 0.14 –
Tie2 Kinase inhibitor No – – –
Bosutinib Yes – – 50
AG1478 Yes 22.8 13 –
Indirubin-3 `-oxime Yes 18.3 4.2 –
Fumagillin No – – –
NS-398 Yes – – 30
HIF-1 Inhibitor No – – –
NVP-BEZ235 Yes – – 10
2-Methoxyestradiol Yes 30.6 10.2 –
Paclitaxel Yes – – ?
Tyrphostin AG490 No – – –
Bestatin No – – –
Acetamide No – – –
E64 No – – –
O6-benzylguanine No – – –
Cyclosporine A No – – –
4-Methylpyrazole hydrochloride No – – –
N-Acetyl-L-cysteine No – – –
Amiodarone hydrochloride No – – –
cis-Diammineplatinum(II) dichloride No – – –
Table includes information about the presence or absence of an anti-angiogenic effect, the IC50 values when it was possible to calculate them or the minimum
concentration that showed an effect when not. T.V: total number of vessels; C.V complete number of vessels.
doi:10.1371/journal.pone.0036690.t004
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block in zebrafish embryos. An explanation could be that although
inhibition of HERG channels has been proposed as a primary test
for screening purposes, several ion currents are involved in the
generation of the cardiac potential. Then, the net effect caused by
Verapamil leads to a shortening of the QT interval.
Table 5. Coefficient of Variation of the angiogenesis assay.
COMPOUND TESTED CONCENTRATION (mM) C.V. FLUORESCENT INTENSITY (%) C.V. TOTAL VESSELS (%)
KRN633 0.03 28.5 13.6
Sunitinib malate 2 7.6 2.2
PD166866 30 13.4 12.4
AG-1296 20 1.1 2.4
Bosutinib 60 7.6 0.7
AG1478 20 17.2 11.2
Sorafenib Tosylate 1 20.8 3.3
NS-398 40 11.6 3.2
2-Methoxyestradiol 10 13 2.6
Calculation of the Coefficient of Variation of the indicated parameters calculated from data obtained after 3 independent experiments carried out with the positive
compounds shown at one dose close to the IC50 or the effective concentration.
doi:10.1371/journal.pone.0036690.t005
Figure 5. Two different phenotypes induced by angiogenesis inhibitors. 24 hpf zebrafish embryos were treated with different inhibitors and
checked for angiogenesis defects at 48 hpf (A) or at 72 hpf (B) as described in material and methods section. (A) Representative fluorescent images of
embryos treated with inhibitors that alter the development of ISVs at the level of sprouting and extension (superior panel) or that perturb later stages
of maturation and/or DLAV formation (lower panel). Compared with control ones, treated embryos present a lower number of incomplete ISVs in the
case of Sorafenib and AG1478 while AG1296 and PD173074 inhibit proper development of the DLAV and the ISVs looks thinner. (B) Representative
fluorescent images of embryos treated with the indicated inhibitors showing the presence of thinner ISVs, some of them disrupted (arrows) and
interrupted DLAV formation (asterisks).
doi:10.1371/journal.pone.0036690.g005
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regulators is endothelial cell tube formation assay [44], [45],
[46], [47]. Although different endothelial cell tube formation
assays that implicate one or more cellular types have been
described as simple, rapid and quantitative, to our knowledge, the
throughput obtained with these in vitro assays has never been
published. Moreover, various days of culture are necessary to
obtain a real tube formation, effects are usually difficult to quantify
and not all of them are sufficiently robust for high-throughput
screening. Apart from the general advantages of a whole organism
assay mentioned above, the impairment of the proper develop-
ment of ISVs in zebrafish embryos has been demonstrated as an
excellent alternative for these in vitro assays [18], [19].
Next, both cardiotoxicity and angiogenesis assays were validat-
ed. For cardiotoxicity assessment, we defined the conditions to
detect potential inducers of QT prolongation mediated by ERG
blockade with a high specificity and sensitivity (14 out of 15 QT
HERG mediated QT prolongation inducers were correctly
detected). We also showed that compounds affecting calcium
(Nitrendipine, Diltiazem, Verapamil) or inhibitors of sodium
channels (Lidocaine) can be detected as bradycardia inducers.
Moreover, the activation of sodium channels by treatment with the
sodium channel opener SDZ-201106 caused type 2:1 arrhythmias
in zebrafish embryos and therefore could be classified as a
potential QT-prolongation inducer. These data lead us to
hypothesize that the characteristic type 2:1 arrhythmias observed
in zebrafish could be related to a delay in the action potential
repolarization. Another possibility could be that SDZ-201106
might be blocking zERG channel as well as sodium channels.
Further work should be done to test these hypotheses.
Among the 35 compounds analyzed, we have detected a low
rate (8.5%) of false negatives (FN): Of the three FN found
(Ziprasidone, L-768763 and Chromanol 293b), Ziprasidone was
the only HERG blocker undetected out of 15 tested. L-768763
and Chromanol 293b are specific Iks channel blockers. The results
with these drugs suggest that zebrafish embryos might not be
expressing Iks or that this type of channel is not totally functional
at the time of the assay (48 hpf). Again, new experiments should be
conducted to demonstrate the functionality of Iks channels at
different development stages of zebrafish embryos. All these data
together indicates that our cardiotoxicity assay was successfully
automated and that zebrafish embryos are an excellent model to
detect cardiotoxic compounds acting through different targets.
The second assay developed was addressed to identify
angiogenesis modulators. Angiogenesis is a cellular process,
exquisitely regulated by which vessels already established, branch
and invade tissues in response to normal or pathological stimulus
[48]. The knowledge of the molecular mechanisms that regulate
angiogenesis is clinically relevant and consequently, the detection
of small molecules that inhibit angiogenesis is interesting for
Pharmaceutical companies mainly focused in the development of
products for oncology and ophthalmology.
As a result of the angiogenesis validation, 15 of the 18 positive
drugs were detected as angiogenesis inhibitors. Moreover, two
distinct phenotypes associated with the alteration of different steps
during the angiogenesis process could also be differentiated.
All the compounds that inhibited VEGFRs (specifically or as
one of the multiple tyrosine kinase targets) induced a clear
perturbation in the sprouting of the endothelial cells with absent or
uncompleted ISVs that were stalled half way. These results
highlight the importance of VEGF growth factors and their
receptors as the predominant regulators of vascular development
[49], [50], also in zebrafish.
Two specific FGFRs (PD173074 for FGFR1 and 3 and
PD166866 for FGFR1) and PDGFRs (AG1296 and PDGFR
tyrosine kinase inhibitor V both for PDGFR a y b) inhibitors were
also tested. While PD166866 and PDGFR tyrosine kinase
inhibitor V induced a strong angiogenesis inhibition indicative of
sprouting and extension defects, treatment with PD173074 and
AG1296 resulted primarily in thinner ISVs rather than incomplete
vessel formation. In fact, these vessels were not functional and
started to be disrupted at 72 hpf. This discrepancy between
phenotypes induced by different inhibitors for the same enzyme is
not surprising. Kinases share similar structural frameworks in their
active sites, so there is great potential for cross reactivity [51]. Our
experience with other FGFR inhibitors tested (data not shown)
and results obtained with a PDGFR inhibitor [52] or after
silencing PDGFRb2 with morpholino [53] indicates that probably
PDGF and FGF regulate lumen formation in the process of
maturation of the ISVs in zebrafish. In fact, different studies
suggest that a combination of FGF2 and PDFG-BB synergistically
promote formation of stable vessels in mammals [54], [55]. All
these data suggest that the phenotype found with PD173074 and
AG1296 is probably the one specific for the inhibition for PDGFR
b2 and FGFR respectively.
Nonselective antiangiogenic agents that target Abl and Src tyr
kinases, EGFR, cyclin-dependent kinases, cyclooxigenase-2
(COX-2), PI3K, and microtubules stabilization also exert an
anti-angiogenic action in zebrafish embryos. However, inhibition
of one of the main regulators of vascular development in
mammals, Tie2 tyr kinase receptor, did not induce any
angiogenesis defect after inhibition in our screening. This result
agrees with previous reports in which a zebrafish mutant line for
Tie2 kinase did not show any defect in ISVs formation [56]
although it participates in heart development. Hif-1 inhibitor was
also not detected in our validation. Although Hif-1 factor is
essential for angiogenesis induction in response to hypoxia
(condition found in solid tumors) [57] to our knowledge its role
in developmental angiogenesis has never been described. There-
fore, even if some pathways are not conserved between zebrafish
and mammals or not all the regulators of pathologic or
developmental angiogenesis are the same, the developed assay
permits the detection of inhibitors of many of the main pathways
that regulate angiogenesis.
Taken together, we have implemented an automated platform
for running screenings using zebrafish embryos for which the most
relevant advantages are the flexibility to implement different types
of assays, the robustness of the methods developed and the
scalability of the system. Importantly, the level of integration of
both assays allows us to run the screenings almost unattended by
laboratory technicians. Furthermore, we provided the results of
the validations performed in two different assays, demonstrating
that automation of screenings using a vertebrate model is feasible.
Materials and Methods
HTS Platform
The HTS platform integrates an embryo sorter adapted from
the Copas XL from Union Biometrica with a larger embryo
reservoir and specific sensors and alarms, two liquid handling
devices (Starlet’s from Hamilton), a plate-feeder carrousel
(Cytomat Hotel from Thermo), an automatic incubator (Cytomat
from Thermo), a reader (fully motorized inverted microscope
Axiovert 200 M from Zeiss and EMCCD camera from Hama-
matsu) and a robotic arm (TX60 from Staubli) as shown in
Figure 1. It also uses several computers that run the applications
and are connected through the network. Finally, Biobide’s main
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Celerra NS20 system from EMC is used for storing the images and
result files.
Compounds Tested in Validation
Angiogenesis validation: NVP-BEZ235, Sorafenib p-Toluenesulfo-
nate salt, Bosutinib and Sunitinib malate salt were purchased from
LC Laboratories; HIF-1 Inhibitor, Paclitaxel, AG1478,
PD166866, Tie2 Kinase Inhibitor, 2-Methoxyestradiol and
KRN633 from Calbiochem; NS-398, AG-1296, PD173074 from
Cayman Chemical; Fumagillin from Tocris bioscience; PDGFR
Tyrosine Kinase Inhibitor V from Merck; ZD6474 from Selleck.
The rest of the compounds were purchased from Sigma-Aldrich.
Cardiotoxicity validation: All compounds were obtained from Sigma,
except SDZ-201106 and Lapatinib that were obtained from
Biomol and Selleck respectively. L-768763 was kindly gifted by
Merck.
Zebrafish Husbandry and Transgenic Lines
Adult zebrafish were housed and maintained in accordance with
standard procedures. All experiments were performed in compli-
ance with the local animal welfare regulations and have been
approved by Biobide’s ethical committee. Embryos were collected
and raised in E3 media according to standard protocol (Nusslein-
Volhard, 2002). For the angiogenesis assay TG(Flk1:copGFP) and
TG(Fli1:EGFP) (Lawson et al, 2002) transgenic zebrafish lines that
express green fluorescent protein GFP under the control of specific
promoters of the vascular system, were used. For the cardiotoxicity
assay transgenic zebrafish embryos expressing CopGFP under the
cardiac-specific promoter Cmlc2 were used.
Cardiotoxicity Assay
Embryos at 48 hpf were automatically dispensed in a 96 well
plate discarding exterior columns and rows and volume was
leveled to 50ml with E3. Compounds were prepared 200 times
concentrated in DMSO. A 1:100 dilution was automatically made
from the stock and 50 ml were added to each embryo to reach the
final concentration. Then, embryos were incubated at 28.5uC for 3
hours. Embryos were not anesthetized to avoid potential beating
alterations.The microscope scanned the wells by columns and a
movie of the beating heart was recorded (512 frames) at
27.5uC60.5 in all cases (except for comparison of temperature
variable). Embryos that moved during video recording were
discarded. Analysable videos (67%) were processed by using non-
commercial Cardio v3.0.0.5 software. One video per embryo from
a minimum of 10 embryos in each treated group were necessary
for statistical analysis.
Angiogenesis Assay
For the angiogenesis assay embryos were obtained and kept at
26.7uC until the time of treatment (22–26 hpf). At this time,
chorions were removed with protease from Streptomyces griseus
(Sigma-Aldrich) (1.5 mg/ml for 6 minutes) and the embryos were
sorted and dispensed 1 per well in a 96 well assay plate. Each
experimental condition was tested in a row with ten embryos.
Embryos were dispensed in an average final volume of 90 mlo fE 3
media. 90 ml of the test items (DMSO and positive control
KRN633 included) previously diluted 100 times were dispensed
into each well of the assay plate containing the embryos to get the
final volume of 180 ml and the desired final concentration.
In the case of Paclitaxel, because the compound precipitated
after the dilution in E3 medium, and the maximum dose tested
(10 mM) was not enough to induce inhibition of angiogenesis, an
injection of 10 nl of the compound at 10 mM diluted in DMSO
was directly injected in the yolk.
The assay plate was incubated at 28.5u during 23–26 hours.
After that, embryos were anesthetized with 10 ml tricaine (final
concentration 0.12%) to prevent their movement and after 12
minutes of incubation the assay plate was placed in the microscope
(Axiovert 200 M). The microscope scanned the wells by columns
and a bright field image and a fluorescent image (2.56magnifi-
cation) were acquired per well. Then, the image analysis was
performed and the result file generated.
Embryo Analysis at 72 hpf
Embryos from the Flk1:copGFP line were treated with the
indicated compounds at 22–23 hpf in 500 ml of E3 in p24 well
plates (5 embryos per well). After 48 hours of treatment embryos
were anesthetized with 10 ml Tricaine (final concentration 0.02%)
and analyzed for the presence of blood circulation and ISVs
development using a Leica M205 FA stereoscope equipped with a
Hamamatsu C10600 camera.
Statistical Analysis
Statistical analysis and graphical representation of the data were
performed using SSPS (Statistical Package for the Social Sciences)
software and Prism (Graph Pad Software) for IC50 calculations
(non linear regression, sigmoidal dose-response with variable
slope). As heartbeat followed a non-Gaussian distribution (skew-
ness value -0.9, p,0,001), a U-Mann-Whitney test was applied to
compare treated versus control groups. In the angiogenesis assay,
for comparisons between two groups, two-tailed t-test was used
assuming unequal variances. For comparisons between more than
two groups one-way analysis of variance followed by Dunnett’s
post-test was applied to compare each data point with vehicle
control.
Supporting Information
Figure S1 Scheduling of the assays developed. The figure
shows an example of scheduling of a typical cardiotoxicity (A) or
angiogenesis assay (B). Each color corresponds to a different task:
dispensation of the embryos (yellow), addition of compound (blue),
drug incubation (green), read out (pink) and transport (grey). The
microscope is the bottle-neck of the platform, thus each plate is
planned to reach the microscope after the reading of the previous
one.
(PPTX)
Figure S2 Effect of the read out temperature and
embryo stage on heart rate. One cell stage embryos were
incubated at 28.5uC until they reached 48hpf (A) and 48, 51 or 54
hpf (B), and plated as described in Material and Methods section.
Heart rates were measured at 51 hpf at two different temperatures
24.5uC and 27.5uC (A) or only at 27.5uC (B). (A) A total of 4 plates
were analyzed for each temperature. Each dot in the graph
represents the heart rate of a single embryo. At 27.5uC the heart
rate was significantly higher that at 24. 5uC( p ,0.001). (B) A total
of 4 plates were analyzed per stage. As shown in the graph no
statistically significant differences were found between the three
stages in the heartbeat.
(PPTX)
Figure S3 Determination of bradycardia threshold. 48
hpf embryos were treated as described in Material and Methods
with 5 mM Thioridazine. The compound was tested on approx-
imately 100 embryos distributed in 10 plates and the graph
represents the ROC curve. 36.5 was chosen as the discriminatory
Zebrafish Drug Screening Platform Validation
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36690value between control and bradycardic heart rates with sensitivity
of 78% and specificity of 70%.
(PPTX)
Table S1 Compounds checked in system validation and their
targets.
(PPTX)
Movie S1 Heart beating of an untreated embryo.
(AVI)
Movie S2 Heart beating of an embryo treated with 50 mM
Lidocaine.
(AVI)
Movie S3 Heart beating of an embryo treated with 5 mM
Terfenadine.
(AVI)
Movie S4 Heart beating of an embryo treated with 10 mM
Cisapride.
(AVI)
Movie S5 Heart beating of an embryo treated with 50 mM
Nitrendipine.
(AVI)
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